Best option for preoperative biliary drainage in Klatskin tumor
A systematic review and meta-analysis

Zengwei Tang, MD\textsuperscript{a}, Yuan Yang, MD\textsuperscript{a}, Wenbo Meng, MD, PhD\textsuperscript{a,b,d,*}, Xun Li, MD, PhD\textsuperscript{a,c,d*}

Abstract
The operative treatment combined with preoperative biliary drainage (PBD) has been established as a safe Klatskin tumor (KT) treatment strategy. However, there has always been a dispute for the preferred technique for PBD technique. This meta-analysis was conducted to compare the biliary drainage-related cholangitis, pancreatitis, hemorrhage, and the success rates of palliative relief of cholestasis between percutaneous transhepatic biliary drainage (PTBD) and endoscopic biliary drainage (EBD), to identify the best technique in the management of KT.

PubMed, EMBASE, and Web of Science were searched systematically for prospective or retrospective studies reporting the biliary drainage-related cholangitis, pancreatitis, hemorrhage, and the success rates of palliative relief of cholestasis in patients with KT. A meta-analysis was performed, using the fixed or random-effect model, with Review Manager 5.3.

PTBD was associated with lower risk of cholangitis (risk ratio [RR] = 0.49, 95% confidence interval [CI]: 0.36–0.67; \(P < .00001\)), particularly in patients with Bismuth-Corlette type II, III, IV KT (RR = 0.50, 95% CI: 0.33–0.77; \(P = .05\)). Compared with EBD, PTBD was also associated with a lower risk of pancreatitis (RR = 0.36, 95% CI: 0.17–0.69; \(P = 0.003\)) and with higher successful rates of palliative relief of cholestasis (RR = 1.20, 95% CI: 1.10–1.31; \(P < .0001\)). The incidence of hemorrhage was similar in these 2 groups (RR 1.29, 95% CI: 0.51–3.27; \(P = .59\)). The risk of biliary drainage-related cholangitis (RR = 1.96, 95% CI: 0.96–4.01; \(P = .06\)) and pancreatitis (RR = 1.62, 95% CI: 0.76–3.47; \(P = .21\)) was similar between endoscopic nasobiliary drainage groups and biliary stenting.

In patients with type II or type III or IV KT who need to have PBD, PTBD should be performed as an initial method of biliary drainage in terms of reducing the incidence of procedure related cholangitis, pancreatitis, and improving the rates of palliative relief of cholestasis. Well-conducted randomized controlled trials with a universal criterion for PBD are required to confirm these findings.

Abbreviations: CI = confidence interval, EBD = endoscopic biliary drainage, EBS = endoscopic biliary stenting, ENBD = endoscopic nasobiliary drainage, KT = Klatskin tumor, NOS = Newcastle-Ottawa Scale, PBD = preoperative biliary drainage, PTBD = percutaneous transhepatic biliary drainage, RR = risk ratio.

Keywords: endoscopic biliary drainage, endoscopic biliary stenting, endoscopic nasobiliary drainage, klatskin tumor, percutaneous transhepatic biliary drainage
1. Introduction

Klatskin tumor (KT), also named as perihilar cholangiocarcinoma or hilar cholangiocarcinoma, was first recognized as a distinct clinical entity first reported by Klatskin on a series of 13 patients in 1975. [1] It is usually classified according to the extent of ductal involvement by tumor, which has been described by Bismuth et al in 1988. [2] This Bismuth classification is a standard for making a decision on resectability of KT and selecting the methods before the surgery. Complete resection of the KT, with negative resection margins, offers the best possibility for long-time survival postoperatively. [3,4] However, liver surgery in cholestatic patients with KT is closely associated with high risks of postoperative morbidity and mortality. [5,6]

In the majority of KT, the first observed symptom was obstructive jaundice, which is related to postoperative morbidity and mortality rates; the mainly lethal factor was considered as hepatic insufficiency. [7] Preoperative biliary drainage (PBD) may cause discomfort because of nasopharyngeal irritation. [8] This Bismuth classification. These adverse outcomes were also assessed between ENBD groups and EBS in 1 subgroup analysis.

2. Methods

2.1. Literature research

A comprehensive literature search (up to November 8, 2016) was performed using PubMed (2000-Novemeber 8, 2016), EMBASE (2000-Novemeber 8, 2016), and Web of Science (2000-Novemeber 8, 2016), restricted to articles published in English. The following keywords were used: “proximal bile duct cancer or hilar bile duct carcinoma or Klatskin tumor or perihilar cholangiocarcinoma or hilar cholangiocarcinoma” AND “percutaneous transhepatic biliary drainage or endoscopic biliary drainage or endoscopic nasobiliary drainage or endoscopic biliary stenting” AND “choolangitis or pancreatitis or complications.” Within the results for those combined keywords, additional filters, publication types were used to exclude the most common article types that did not report clinical study results (reviews and case studies). Animal studies were also excluded where possible (Appendix I for PubMed search strategy). We also searched by hand the references of studies included in the original search to identify studies missed on the initial search. All procedures were approved by the ethics committee for human experiments of the First Hospital of Lanzhou University.

2.2. Study selection criteria

Published studies were included if they met the following criteria: observational design (retrospective or prospective cohort or case control) or interventional design (random or non-randomized); subjects with KT who accepted the management of PBD (PTBD or EBD); the drainage related complications were reported; and patients not treated previously with portal vein embolization. Studies included PTBD or EBD only, and subjects with another biliary tract carcinoma (e.g., distal cholangiocarcinoma, intrahepatic cholangiocarcinoma, gall bladder carcinoma, carcinoma of pancreas, and region lymph node metastases) were excluded.

2.3. Data extraction

Data extraction was carried out independently by 2 investigators (ZT and YY), with the discrepancies resolved by the consensus of these 2 investigators (Any disagreement on a conflicting study was resolved by full discussion). The information including author, year of publication, country, cancer type (Bismuth-Corlette type) and patients number of each type, type of PBD, mean age and range, sex, the success rates of palliative relief of cholestasis, and the incidence of cholangitis, pancreatitis, and hemorrhage were recorded from each study. The methodological quality of comparative observational studies was assessed by using the Newcastle-Ottawa Scale (NOS). A score of 0 to 9 was assigned to each study. [29]

2.4. Definition of outcomes

The primary endpoint of the meta-analysis was the incidence of biliary drainage-related choanalgitis. The second endpoint was the incidence of pancreatitis, hemorrhage, and the success rates of palliative relief of cholestasis. We assessed the procedure-related choanalgitis and pancreatitis based on consensus criteria. [30] The procedure-related hemorrhage was defined arbitrarily as bleeding that required transfusion or additional intervention, and the success rates of palliative relief of cholestasis were defined arbitrarily as a palliation of cholestasis successfully after operation, or patients underwent the PTBD or EBS or ENBD successfully without converting to another type of PBD.

2.5. Statistical analysis

The incidence of drainage-related choanalgitis was the primary outcome measure, and the impact of pancreatitis, hemorrhage,
and success rates of palliative relief of cholestasis associated with biliary drainage procedure were the second endpoints. The Mantel-Haenszel method was used to pool data of clinical outcomes. Risk ratio (RR) analysis was used to generate an overall effect estimate of both outcomes. The fixed-effect model was used in case of there was low heterogeneity in the variables among the studies. Moreover the random-effect model was used when there was significant heterogeneity. Intention-to-treat data were extracted from all studies. We used the $\chi^2$ test to evaluate heterogeneity between trials and the $I^2$ statistic to assess the extent of the inconsistency, wherein an $I^2$ test $>50\%$ suggests significant heterogeneity. Statistical heterogeneity was assessed using an $I^2$ test and was categorized into low ($<50\%$), moderate ($51\%$-$75\%$), or high ($>75\%$) according to predefined criteria. Forest plots were generated by using standard techniques to summarize the included studies, with horizontal lines representing 95\% confidence interval (CI) and the area of each square indicating the RR point estimate. The overall summary estimate under fixed-effect or random-effect with its 95\% CI was shown, and the vertical line was at the null value (RR = 1.0). Publication bias was evaluated for biliary drainage cholangitis analysis by Egger test and funnel plot. Moreover, a $P < 0.05$ for Egger test was considered representative of significant publication bias. All statistical analyses were carried out with the software Review Manager 5.3 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration 2014).

3. Results
The initial search identified 546 articles based on the searching key words. Nine retrospective cohort studies were eligible for inclusion in this systematic review and meta-analysis (Fig. 1), and of them, 1 study just compared the biliary drainage-related complications occurred in EBS groups and ENBD. The remaining studies compared the complications associated with biliary drainage procedure occurred in PTBD groups and EBD. One study reported by Hirano et al with 141 patients with KT included 14 patients with intrahepatic cholangiocarcinoma located at the perihilar region (6 in PTBD group and 8 in EBD group).

Characteristics of studies included are outlined in Table 1 and Table 2 and “Supplementary Table 1”, http://links.lww.com/MD/B914. The Table 1 provides details about the 9 studies that were included in the systematic review and
meta-analysis. The incidence of complications associated with PBD was summarized in Table 2, and a total number of 1030 patients with KT were enrolled in the analysis. Supplementary Table 1, http://links.lww.com/MD/B914 presents the definition of procedure-related cholangitis, pancreatitis, hemorrhage, and the success rates of palliative relief of cholestasis reported by studies included in this meta-analysis. No randomized control trial was included, so the quality of the studies included in the meta-analysis was assessed by the NOS scale. Overall, there is an average medium quality of 5 of 9 stars in all studies (range 5–6).
3.1. Primary endpoint: the incidence of cholangitis in PTBD groups versus in EBD groups

Seven studies[17,18,20,23–25,32] (n = 912 patients) reported the incidence of cholangitis in PTBD groups and EBD. The RR and 95% CI for each study and the pooled RR are shown in Figure 2. The overall summary estimated RR was 0.49 (95% CI: 0.36–0.67; P < .00001). Heterogeneity testing revealed that $I^2 = 32\%$ and the $P$ for heterogeneity = .18, using a fixed-effect model. In subgroup 2.1.1 (Fig. 2), patients with type II, III, IV KT (RR = 0.50, 95% CI: 0.33–0.77; $P = .05$). Heterogeneity testing revealed that $I^2 = 57\%$ and the $P$ for heterogeneity = .10. And in subgroup 2.1.2 (Fig. 2), the summary estimated RR was 0.49 (95% CI: 0.31–0.76; $P = .001$). Heterogeneity testing revealed $I^2 = 23\%$ and the $P$ for heterogeneity is .24.

3.2. Secondary endpoints: the incidence of pancreatitis, hemorrhage, and the success rates of palliative relief of cholestasis

Eight studies[17–21,24,25,32] provided the data (n = 912 patients) on the incidence of pancreatitis, and the RR and 95% CI for each study and the pooled RR are shown in Figure 3. The overall summary estimated RR was 0.35 (95% CI: 0.17–0.69; $P = .003$). Heterogeneity testing revealed $I^2 = 42\%$ and the $P$ for heterogeneity = .10, using a fixed-effect model.

The hemorrhage data were provided in 5 studies,[17–19,25,32] but 1 study[17] reported by Kloek et al was excluded from the analysis of the incidence of hemorrhage, as it did not meet the eligibility criteria for hemorrhage. The RR and 95% CI for remaining 4 studies and the pooled RR are shown in Figure 4. The overall summary estimated RR was 1.29 (95% CI: 0.51–3.27; $P = .59$). Heterogeneity testing revealed that $I^2 = 0\%$ and the $P$ for heterogeneity = .001, using fixed-effect model.

In ENBD versus EBS, the incidence of cholangitis and pancreatitis were reported by 3 studies.[20,23,24] As described in Figure 6, the overall summary estimated RR of cholangitis was 1.96 (95% CI: 0.96–4.01; $P = .06$). Heterogeneity testing revealed that $I^2 = 63\%$ and the $P$ for heterogeneity = .07, using a random-effect model. Moreover, the pooled RR of pancreatitis was 1.62 (95% CI: 0.76–3.47; $P = .21$). Heterogeneity testing revealed that $I^2 = 0\%$ and the $P$ for heterogeneity = .77, using a fixed-effect model.

Table 3 provides a summary of results.

3.3. Publication bias

The funnel plot (Fig. 7) shows no evidence of noticeable asymmetry. Egger test similarly showed no publication bias (Egger $t$ value = 0.000, $P = .282$).
3.4. Additional analyses

Comparing the incidence of cholangitis between PTBD and EBD, there was high heterogeneity ($I^2$ up to 57%), as we included 8 studies\cite{17-21,23-25,32} (Supplementary Figure 1, http://links.lww.com/MD/B914). The RR was 0.59 (95% CI: 0.37–0.92; $P=.02$). Visual inspection of the forest plot showed that 1 study\cite{21} reported by Hirano et al\cite{21} with 141 patients with KT was obviously discrepant from the remaining studies, a similar outcome was represented after this study was removed, and the RR was 0.49 (95% CI: 0.36–0.67; $P<.0001$). Heterogeneity testing revealed that $I^2=32\%$ and the $P$ for heterogeneity was .18. The exact cause of this heterogeneity may be related to the elements in the selection of populations, compared with other 7 studies; 14 subjects in the study reported by Hirano et al had been diagnosed with KT and intrahepatic cholangiocarcinoma located in the perihilar region.

4. Discussion

Complete resection combined surgery has been representing the only treatment for KT with curative intent\cite{36-39}; herein, the chemotherapy and neoadjuvant therapy were widely reported to remain poorly characterized, and lack postoperative benefit.\cite{33-36} However, varying definition of resectability criteria, surgical approach, and operational strategies have been applied to regions, in particular between Western (USA and Europe) and Eastern....
Secondary outcomes

| Comparison                     | Outcome                        | Studies (participants) | Risk ratio (95% CI) | Test for heterogeneity |
|-------------------------------|--------------------------------|------------------------|---------------------|------------------------|
| PTBD vs. EBD (Fig. 2)         | The incidence of cholangitis   | 7 (771)                | 0.49 (0.36–0.67)    | .18                    | .32%                  |
| PTBD vs. EBD (Fig. 3)         | The incidence of pancreatitis  | 8 (912)                | 0.35 (0.17–0.69)    | .10                    | 42%                   |
| PTBD vs. EBD (Fig. 4)         | The success rates of palliative | 4 (454)                | 1.29 (0.51–2.27)    | .34                    | 10%                   |
| PTBD vs. EBD (Fig. 5)         | The incidence of hemorrhage    | 6 (653)                | 1.20 (1.10–1.31)    | .08                    | 49%                   |
| EBD vs. ENBD (Fig. 6)         | Cholangitis rate%              | 3 (253)                | 1.96 (0.96–4.01)    | .07                    | 63%                   |
|                               | Pancreatitis rate%             | 3 (253)                | 1.62 (0.76–3.47)    | .77                    | 0%                    |

Note: C = confidence interval, EBD = endoscopic biliary drainage, ENBD = endoscopic naso-biliary drainage, PTBD = percutaneous transhepatic biliary drainage.

The second outcomes showed that PTBD is associated with lower risk of pancreatitis and with a higher success rate of palliative relief of cholestasis compared with that of EBD. The hemorrhage rate was similar in these 2 groups. The incidence of cholangitis and pancreatitis were similar (ENBD vs. EBD) showed by another subgroup analysis (Fig. 6). Although the 3 of 9 studies included in this review reported the few incidence of seeding metastasis in PTBD group (8/414, 1.93%), and no data on the prevalence of seeding metastasis was reported in EBD groups, it is a fact that the seeding metastasis may not be limited to PTBD; seeding metastasis associated with endoscopic drainage methods also have been reported.

Despite several encouraging data were extracted, this meta-analysis still has limitations and strengths. First, this is a study-level meta-analysis of retrospective observational studies; therefore, the differences in measurements among literature still should not be underestimated, including the indication for PBD, the drainage time, the diameter of drainage tube, the biliary stent size, the operation time of drainage procedure and the level of proficiency of operators, and the timing of using antibiotics and the type of antibiotics. Second, most available literatures did not report the complications of each type of KT completely, and 4 studies included in this meta-analysis just provided a total number of complications in EBD group; the complication of ENBD or EBD still remains unclear. Third, there were just 2 patients with type IKT of 1 study incorporated into subgroup 2.1.1 (Fig. 2) based on the percentage values the limited sample number restricted the accuracy of the study. Fourth, although the definition of procedure-related cholangitis and hemorrhage among studies.
included in the meta-analysis met the predefined criteria, the definition of procedure-related cholangitis and hemorrhage are not unanimous among these included studies. Finally, only published studies were included in this meta-analysis, and the population data were only obtained from 4 countries (Japan, Korea, Canada, The Netherlands), so these results should be interpreted with caution as in most meta-analysis.

However, despite the limitation listed, this study still the first systematic analysis assessing the biliary drainage-related complications for patients with KT, and the low heterogeneity and highly significant results were obtained with minimal evidence of bias for biliary drainage-related complications analysis.

Genomic, epigenetic, and molecular characterization of KT in an individual patient might provide valuable information on pathogenesis, prognosis, and chemosensitivity, thus indicating the best characterized therapeutic options for each patient as well as new potent. However, as of now, imaging characteristics of KT directly affect the choice of radical resection since the limited understanding of the pathogenesis of KT, especially in molecular pathology. Although KT typically involves the biliary confluence according to imaging characteristics (Bismuth–Corlette type), in most cases, it extends proximally to second- and third-order biliary branches. Therefore, for KT with obstructive jaundice and poor condition, the efficient and sufficient PBD are needed to create a safer environment before surgery.

In conclusion, this systematic review and meta-analysis provide the evidence that PTBD did not increase the risk of procedure related hemorrhage, and for patients with type II or type III or IV KT who need to have PBD, PTBD should be performed as the initial method of biliary drainage in terms of reducing the incidence of procedure related cholangitis, pancreatitis, and improving the rates of palliative relief of cholestasis.

Further randomized control trials with universal criteria for PBD, which are based on the Bismuth–Corlette classification (i.e., the drainage time, diameter of drainage tube, the biliary stent size, the operation time of drainage procedure, the level of pro-PBD, which are based on the Bismuth-Corlette classification), could improve the rates of palliative relief of cholestasis and future liver remnant volume determine the risk of liver failure in patients undergoing resection for hilar cholangiocarcinoma.

References

[1] Bismuth H, Corlette MB. Intrahepatic cholangioenteric anastomosis in carcinoma of the hilar of the liver. Surg Gynecol Obstet 1975;140:170–8.
[2] Bismuth H, Castaing D, Traray O. Resection or palliation: priority of surgery in the treatment of hilar cancer. World J Surg 1988;12:39–47.
[3] Byrnes V, Alfahal N. Cholangiocarcinoma of the Hepatic Hilum (Klatskin Tumor). Curr Treat Options Gastroenterol 2002;5:87–94.
[4] Popescu D, Dumitrescu T. Curative-intent surgery for hilar cholangio-carcinoma: prognostic factors for clinical decision making. Langenbeck's Arch Surg 2014;399:693–705.
[5] Nuzzo G, Giulianu F, Arifdo F, et al. Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients. Arch Surg 2012;147:26–34.
[6] Kaiser GM, Paul A, Gouarakis G, et al. Novel prognostic scoring system after surgery for Klatskin tumor. Am Surg 2013;79:90–5.
[7] Nagano M, Kamiya J, Utsaka K, et al. Complications of hepatectomy for hilar cholangiocarcinoma. World J Surg 2001;25:1277–83.
[8] Iacono C, Ruzzenente A, Campagnaro T, et al. Role of perioperative biliary drainage in jaundiced patients who are candidates for pancreaticoduodenectomy or hepatic resection: highlights and drawbacks. Ann Surg 2013;257:191–204.
[9] van der Gaag NA, Klok EJ, de Castro SM, et al. Preoperative biliary drainage in patients with obstructive jaundice: history and current status. J Gastrointest Surg 2009;13:814–20.
[10] Gomaa DJ. Multicentre European study of preoperative biliary drainage for hilar cholangiocarcinoma. Br J Surg 2013;100:283–4.
[11] Sakata J, Shirai Y, Tsuuya Y, et al. Preoperative cholangitis independently increases in-hospital mortality after combined major hepatic and bile duct resection for hilar cholangiocarcinoma. Langenbecks Arch Surg 2009;394:1065–72.
[12] Nagano M, Etaba T, Yokoyama Y, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann Surg 2013;258:129–40.
[13] Yokoyama Y, Etaba T, Igi M, et al. The adverse effects of preoperative cholangitis on the outcome of portal vein embolization and subsequent major hepatectomies. Surgery 2014;156:190–6.
[14] Wiggers JK, Coelen RJ, Rauws EA, et al. Preoperative endoscopic versus percutaneous transhepatic biliary drainage in potentially resectable perihilar cholangiocarcinoma (DRAINAGE trial): design and rationale of a randomized controlled trial. BMC Gastroenterol 2015;15:20.
[15] Ribeiro D, Zimmitti G, Alosa TA, et al. Preoperative cholangitis and future liver remnant volume determine the risk of liver failure in patients undergoing resection for hilar cholangiocarcinoma. J Am Coll Surg 2016;223:87–97.
[16] dos Santos JS, Junior WS, Modena JL, et al. Effect of preoperative endoscopic decompression on malignant biliary obstruction and postoperative infection. Hepatogastroenterology 2003;50:45–7.
[17] Klok EJ, Van der Gaag NA, Aziz Y, et al. Endoscopic and percutaneous preoperative biliary drainage in patients with suspected hilar cholangiocarcinoma. J Gastrointest Surg 2010;14:119–25.
[18] Walter T, Ho CS, Horgan AM, et al. Endoscopic or percutaneous biliary drainage for Klatskin tumors. J Vasc Interv Radiol 2013;24:113–21.
[19] Kim KM, Park JW, Lee JK, et al. A comparison of preoperative biliary drainage methods for perihilar cholangiocarcinoma: endoscopic versus percutaneous transhepatic biliary drainage. Gut Liver 2015;9:791–9.
[20] Kawakami H, Kuwata M, Onodera M, et al. Endoscopic nasobiliary drainage is the most suitable preoperative biliary drainage method in the management of patients with hilar cholangiocarcinoma. J Gastroenterol 2011;46:242–8.
[21] Hirano S, Tanaka E, Tsuschikawa T, et al. Oncological benefit of preoperative endoscopic biliary drainage in patients with hilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2014;21:533–40.
[22] Paik WH, Loganathan N, Hwang JH. Preoperative biliary drainage in hilar cholangiocarcinoma: When and how? World J Gastroenterol Endosc 2014;6:68–73.
[23] Kawakubo K, Kawakami H, Kuwata M, et al. Lower incidence of complications in endoscopic nasobiliary drainage for hilar cholangiocarcinoma. World J Gastroenterol Endosc 2016;8:385–90.
[24] Jo JH, Chung MJ, Han DH, et al. Best options for preoperative biliary drainage in patients with Klatskin tumors. Surg Endosc 2017;31:422–9.
[25] Paik WH, Park YS, Hwang JH, et al. Palliative treatment with self-expandable metallic stents in patients with advanced type III or IV hilar cholangiocarcinoma: a percutaneous versus endoscopic approach. Gastrointest Endosc 2009;69:55–62.
[26] Sakata J, Shirai Y, Wakai T, et al. Catheter tract implantation metastases associated with percutaneous biliary drainage for extrapancreatic cholangiocarcinoma. World J Gastroenterol 2005;11:7024–7.
[27] Maguchi H, Takahashi K, Katanuma A, et al. Preoperative biliary drainage for hilar cholangiocarcinoma. J Hepatobiliary Pancreat Surg 2007;14:441–6.
[28] Kitahata Y, Kawai M, Tani M, et al. Preoperative cholangitis during biliary drainage increases the incidence of postoperative severe complications after pancreatectoduodenectomy. Ann J Surg 2014;208:1–10.
[29] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603–5.
[30] Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991;37:383–93.
[31] Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60.
[32] Lee SH, Park JK, Yoon WJ, et al. Optimal biliary drainage for inoperable Klatskin’s tumor based on Bismuth type. World J Gastroenterol 2007;13:3948–55.
[33] Banales JM, Cardinale V, Carpio G, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261–80.
[34] Malhi H, Gores GJ. Review article: the modern diagnosis and therapy of cholangiocarcinoma. Aliment Pharmacol Ther 2006;23:1287–96.
[35] Valle JW, Furuse J, Jitlal M, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol 2014;25:391–8.
[36] Zaydfudim VM, Wang AY, de Lange EE, et al. IgG4-associated cholangitis can mimic hilar cholangiocarcinoma. Gut Liver 2015;9:556–60.
[37] Song SC, Choi DW, Kow AW, et al. Surgical outcomes of 230 resected hilar cholangiocarcinoma in a single centre. ANZ J Surg 2013;83:268–74.
[38] Mansour JC, Aloia TA, Crane CH, et al. Hilar cholangiocarcinoma: expert consensus statement. HPB (Oxford) 2015;17:691–9.
[39] Sano T, Shimada K, Sakamoto Y, et al. One hundred two consecutive hepatobiliary resections for perihilar cholangiocarcinoma with zero mortality. Ann Surg 2006;244:240–7.
[40] ten Hoopen-Neumann H, Gerhards MF, van Gulik TM, et al. Occurrence of implantation metastases after resection of Klatskin tumors. Dig Surg 1999;16:209–13.